ABSTRACT: The incidence of ovarian carcinoma increases with advancing age, peaking during the 7th decade of life and remaining elevated until age 80 years. Despite the high prevalence of ovarian cancer in the elderly, the management of these patients is often less aggressive than that of their younger counterparts. As a result, many elderly cancer patients receive inadequate treatment. However, data do not support the concept that age, per se, is a negative prognostic factor. In fact, the majority of elderly patients are able to tolerate the standard of care for ovarian cancer including initial surgical cytoreduction followed by platinum and taxane chemotherapy. Because functional status has not demonstrated a reliable correlation with either tumor stage or comorbidity, each patient’s comorbidities should be assessed independently. For elderly patients with significant medical comorbidity, the extent of surgery and aggressiveness of chemotherapy should be tailored to the extent of disease, symptoms, overall health, and life goals. In addition, enhanced cooperation between geriatricians and oncologists may assist the pretreatment assessment of elderly patients and improve treatment guidelines in this population.
Dramatic improvements in health care and a decrease in mortality have resulted in an increase in life expectancy among people living in developed countries. In Western countries, a woman's life expectancy was 81.1 years in 1991 and is expected to reach 90.4 years by 2020.[1,2] As a result, the number of cancer-bearing patients aged 70 years and older may also be expected to increase.[3-5] The incidence of ovarian carcinoma rises with advancing age, peaks during the 7th decade of life, and remains elevated until age 80 years . Malignant ovarian neoplasms manifest after age 65 in 30% to 40% of patients.[6,7] Despite the high prevalence of this disease in the elderly, the management of these patients is often less aggressive than that of their younger counterparts, with the result being that many elderly patients receive inadequate treatment.[8-12]
Standard Management for Ovarian Cancer
Approximately 75% of patients with epithelial ovarian cancer are diagnosed when their disease has spread throughout the peritoneal cavity. Most commonly, patients will present with abdominal discomfort or pain. This is generally followed closely by abdominal distention due to the presence of intra-abdominal masses and/or malignant ascites. Gastrointestinal symptoms are nonspecific but include nausea, early satiety, constipation or obstipation, and, less frequently, urinary symptoms. If disease has progressed to involve the lungs by the presence of pulmonary metastases or malignant pleural effusions, the patient may complain of shortness of breath and lethargy.
The 5-year survival of patients with epithelial ovarian cancer correlates directly with tumor stage. The International Federation of Gynecology and Obstetrics (FIGO) staging system, revised in 1985, is presented in Table 1. With the exception of stage IV disease, which can be diagnosed by a cytologically positive pleural fluid, computed tomography-guided biopsy of intraparenchymal liver lesions, or other pathologic evidence of distant spread, the stage of disease is only accurately determined by an exploratory surgical assessment (ie, laparotomy or laparoscopy).
Laparotomy should be performed through a vertical midline incision to allow access to the upper abdomen. Peritoneal lavage or aspiration of ascites is performed to obtain specimens for cytologic analysis. Suspicious areas throughout the abdomen and pelvis, including adhesions, should be biopsied with separate specimens obtained from the pelvis, right and left paracolic gutters, and the undersurfaces of the right and left hemidiaphragms. All intestinal surfaces should be evaluated, and an omentectomy with random peritoneal biopsies should be performed. Pelvic and aortic lymph node sampling is also required.
When the staging is thorough and methodical, a significant number of patients initially thought to have localized disease will be upstaged. In a report by Young and colleagues, 31% of women thought to have stage I or II disease at initial surgery were upstaged at repeat surgical staging. Of these patients, 77% were upstaged to stage III. In a report by McGowan et al, gynecologic oncologists performed adequate surgical staging in 97% of cases, compared to 52% of cases for obstetrician/gynecologists and 35% of cases for general surgeons. In this report, 46% of the 291 women evaluated, had been inadequately staged.
In addition to the prognostic importance of accurate staging, surgical cytoreduction (or debulking) has proven to be an integral component in the management of epithelial ovarian cancer. The volume of residual disease following cytoreductive surgery is inversely related to survival.[16-19] Current criteria for optimal cytoreduction imply residual tumor nodules no greater than 1 cm in diameter. Patients who have undergone optimal cytoreduction have approximately a 22-month median survival advantage compared to patients with suboptimal cytoreduction (residual disease > 1 cm in maximum diameter). Hoskins and colleagues analyzed data from the Gynecologic Oncology Group and noted a significant improvement in survival among patients with 1- to 2- cm residual disease compared to those with greater than 2-cm residual disease.[ 20]
In addition to the survival benefits of cytoreductive surgery, recent reports also confirm that aggressive primary cytoreductions are associated with minimal morbidity and mortality when performed by experienced surgeons. Most studies supporting the survival benefit of cytoreductive surgery have enrolled patients with both stage III and IV disease. Four recent retrospective reports have examined cytoreductive surgery separately in patients with stage IV disease and have consistently demonstrated a statistically significant improvement in survival when a small volume of residual disease remains.[22-24]
Surgery alone rarely produces cure in ovarian cancer patients. Chemotherapy agents from a wide variety of classes have demonstrated activity against ovarian cancer. With the establishment of platinum-based therapy and the introduction of the taxanes, the past 2 decades have seen dramatic improvements in response to chemotherapy and progression-free survival.
Paclitaxel was reported to have significant activity in advanced ovarian carcinoma in 1989. After a series of phase I and II trials established the activity of paclitaxel, two prospective randomized trials comparing cisplatin plus paclitaxel vs cisplatin plus cyclophosphamide (Cytoxan, Neosar) demonstrated the superiority of the paclitaxel-containing regimen.[26,27] Subsequent prospective randomized trials compared paclitaxel/carboplatin (Paraplatin) vs paclitaxel/cisplatin, demonstrating decreased toxicity with the carboplatin regimen and no difference in efficacy.[28,29] With these results, paclitaxel plus carboplatin is now considered first-line treatment for most patients with advanced ovarian cancer.
Patterns of Care
In one of the earliest published reports to examine patterns of care among elderly patients with ovarian cancer, Ries analyzed data for over 22,000 women diagnosed between 1973 and 1987 within the Surveillance, Epidemiology, and End Results (SEER) program. When stratified by stage, age was a significant determinant of survival. The 5-year survival rate for women less than age 45 was 45%, compared to 8% for those age 85 and over. Over 40% of women over 85 did not receive definitive treatment for their disease. In addition, when treatment was given, younger women received multimodality therapy more often than did their older counterparts, who received more single-modality treatments such as surgery, chemotherapy, or hormonal therapy alone.
Further evidence that older women received less aggressive therapy and had poorer survival rates was published in 1994. Hightower and colleagues[ 12] analyzed data from the American College of Surgeons Cancer Commission to investigate differences in patterns of care among the elderly. This study compared survival and care in two patient groups- those age 80 or older vs those under 80. Of 12,316 patients diagnosed between 1983 and 1988, 1,115 were at least 80 years old. Survival was significantly lower among patients in the older group. Most elderly ovarian cancer patients were cared for by nononcologists such as general surgeons (31%) and obstetrician/gynecologists (29%). They also received fewer total abdominal hysterectomies, bilateral salpingo-oophorectomies, and omentectomies than their younger counterparts. Optimal tumor debulking rates were significantly lower for women age 80 or older, and these patients were less likely than younger patients to be given adjuvant chemotherapy (42% vs 69%, P < .0001).
It was recently reported that, although 60% of cancers arise in people over age 65, only 20% to 40% of these patients are enrolled in phase II and III trials, and the majority of patients in these trials are less than age 70.[30,31] Markman et al reported on the Memorial Sloan-Kettering Cancer Center experience regarding enrollment of women with ovarian cancer into clinical trials after primary surgical therapy. A total of 46% of the younger patients were entered into an intensive initial chemotherapy trial, compared to 17% of older patients. The reported reason for the lower enrollment of older patients was an excessive prevalence of comorbid conditions such as heart disease. In addition, the rate of referrals to this institution for both initial treatment and salvage therapy was fourfold higher among younger women compared to their older counterparts. This observation suggests that older patients are less likely to be referred for secondary experimental programs.
Recent reports have also demonstrated that older women with ovarian cancer are less likely to receive the standard recommended treatment or be seen by a gynecologic oncologist in the course of their treatment.[ 34] Carney and colleagues conducted a statewide populationbased study in Utah between 1992 and 1998. Among the 848 cases of epithelial ovarian cancer identified, fewer than 25% of women over age 70 were seen by a gynecologic oncologist, compared to 55% of women aged 40 to 59 and 42.6% of those aged 60 to 69. In the same study, patients with advanced disease experienced a significant survival advantage when a gynecologic oncologist was involved in their care.
1. Ceccaroni M, D’Agostino G, Ferrandina
G, et al: Gynecologic malignancies in elderly
patients: Is age 70 a limit to standard-dose
chemotherapy? An Italian retrospective toxicity
multicentric study. Gynecol Oncol 85:445-
2. Lesur A, Riso M: Evaluation of elderly
patients for fitness to receive treatment. Oncol
Pract 2:9-11, 1998.
3. Aapro MS: Geriatric oncology still has a
long way to go. Oncol Pract 2:2, 1998.
4. Boyle P: Trends in cancer mortality in
Europe. Eur J Cancer 28:7-8, 1992.
5. Ceccaroni M, De Iaco P, Scambia G, et al:
Chemotherapy in elderly gynecologic cancer
patients aged over 70 years: Facts and controversies.
Womens Oncol Rev 2:385-394, 2002.
6. Pecorelli S, Odicino F, Maisonneuve P,
et al: Carcinoma of the ovary. Annual Report
on the Results of Treatment of Gynecological
Cancer. J Epidemiol Biostat 3:75-102, 1998.
7. Berek JS: Epithelial ovarian cancer, in
Berek JS, Hacker NF (eds): Practical Gynecologic
Oncology, 3rd ed, p 457. Philadelphia,
Lippincott Williams & Wilkins, 2002.
8. Fentiman IS: Denying surgery to elderly
people with cancer. Oncol Pract 2:12, 1998.
9. Fentiman IS, Tirelli U, Monfardini S, et
al: Cancer in the elderly: Why so badly treated?
Lancet 335:1020-1022, 1990.
10. Berkman B, Rohan B, Sampson S:
Myths and biases related to cancer in the elderly.
Cancer 74(7 suppl):2004-2008, 1994.
11. Ries LA: Ovarian cancer. Survival and
treatment differences by age. Cancer 71
(2 suppl):524-529, 1993.
12. Hightower RD, Nguyen HN, Averette
HE, et al: National survey of ovarian carcinoma.
IV: Patterns of care and related survival
for older patients. Cancer 73:377-383, 1994.
13. Ozols RF, Rubin SC, Thomas GM,
et al: Epithelial ovarian cancer, in Hoskins
WJ, Perez CA, Young RC (eds): Principles
and Practice of Gynecologic Oncology 3rd ed,
p 981. Philadelphia, Lippincott Williams &
14. Young RC, Decker DG, Wharton JT,
et al: Staging laparotomy in early ovarian cancer.
JAMA 250:3072-3076, 1983.
15. McGowan L, Lesher LP, Norris HJ,
et al: Misstaging of ovarian cancer. Obstet
Gynecol 65:568-572, 1985.
16. Delgado G, Oram DH, Petrilli ES: Stage
III epithelial ovarian cancer: The role of maximal
surgical reduction. Gynecol Oncol 18:293-
17. Vogl SE, Pagano M, Kaplan BH, et al:
Cisplatin based combination chemotherapy for
advanced ovarian cancer: High overall response
rate with curative potential only in
women with small tumor burdens. Cancer
18. Redman JR, Petroni GR, Saigo PE,
et al: Prognostic factors in advanced ovarian
carcinoma. J Clin Oncol 4:515-523, 1986.
19. Louie KG, Ozols RE, Myers CE, et al:
Long-term results of cisplatin-containing combination
chemotherapy regimen for the treatment
of advanced ovarian carcinoma. J Clin
Oncol 4:1579-1585, 1986.
20. Hoskins WJ, McGuire WP, Brady MF,
et al: The effect of diameter of largest residual
disease on survival after primary cytoreductive
surgery in patients with suboptimal residual
epithelial ovarian carincoma. Am J Obstet
Gynecol 170:974-979, 1994.
21. Venesmaa P, Ylikorkala O: Morbidity
and mortality associated with primary and repeat
operations for ovarian cancer. Obstet Gynecol
22. Bristow RE, Montz FJ, Lagasse LD,
et al: Survival impact of surgical cytoreduction
in stage IV epithelial ovarian cancer. Gynecol
Oncol 72:278-287, 1999.
23. Curtin JP, Malik R, Venkatraman ES,
et al: Stage IV ovarian cancer: Impact of surgical
debulking. Gynecol Oncol 64:9-12, 1997.
24. Liu PC, Benjamin I, Morgan MA, et al:
Effect of surgical debulking on survival in
stage IV ovarian cancer. Gynecol Oncol 64:4-
25. McGuire WP, Ozols RF: Chemotherapy
of advanced ovarian cancer. Semin Oncol
26. McGuire WP, Hoskins WJ, Brady MF,
et al: Cyclophosphamide and cisplatin compared
with paclitaxel and cisplatin in patients
with stage III and stage IV ovarian cancer. N
Engl J Med 334:1-6, 1996.
27. Stuart G, Bertelson K, Mangioni C,
et al: Updated analysis shows a highly significant
improved overall survival (OS) for cisplatin-
paclitaxel as first line treatment of
advanced ovarian cancer; mature results of the
EORTC-GCCG, NOCOVA, NCTC, CT and
Scottish Intergroup Trial (abstract). Proc Am
Soc Clin Oncol 17:361, 1998.
28. du Bois A, Lueck HJ, Meier W, et al:
Cisplatin/paclitaxel vs carboplatin/paclitaxel
in ovarian cancer: Update of an Arbeitsgermeinschaft
(AGO) Study Group Trial (abstract 1374). Proc
Am Soc Clin Oncol 18:356a, 1999.
29. Ozols RF, Bundy BN, Fowler J, et al:
Randomized phase II trial of cisplatin/paclitaxel
versus carboplatin/paclitaxel in optimal stage
III epithelial ovarian cancer: A Gynecologic
Oncology Group trial (GOG 158) (abstract
1373). Proc Am Soc Clin Oncol 18:356a, 1999.
30. Aapro M, Extermann M, Repetto L:
Evaluation of the elderly with cancer. Ann
Oncol 11(suppl 3):223-229, 2000.
31. Monfardini S, Sorio R, Boes GH, et al:
Entry and evaluation of elderly patients in
European Organization for Research and Treatment
of Cancer (EORTC) new drug development
study. Cancer 76:333-338, 1995.
32. Markman M, Lewis JL Jr, Saigo P, et al:
Epithelial ovarian cancer in the elderly. The
Memorial Sloan-Kettering Cancer Center experience.
Cancer 71(2 suppl):634-637, 1993.
33. Munoz KA, Harlan LC, Trimble EL:
Patterns of care for women with ovarian caner
in the United States. J Clin Oncol 15:3408-
34. Carney ME, Lancaster JM, Ford C, et
al: A population-based study of patterns of
care for ovarian cancer: Who is seen by a
gynecologic oncologist and who is not? Gynecol
Oncol 84:36-42, 2002.
35. Cloven NG, Manetta A, Berman ML, et
al: Management of ovarian cancer in patients
older than 80 years of age. Gynecol Oncol
36. Bruchim I, Altaras M, Fishman A: Age
contrasts in clinical characteristics and pattern
of care in patients with epithelial ovarian cancer.
Gynecol Oncol 86:274-278, 2002.
37. Edmonson JH, Su J, Krook JE: Treatment
of ovarian cancer in elderly women. Mayo
Clinic North Central Cancer Treatment Group
studies. Cancer 71(2 suppl):615-617, 1993.
38. Monfardini S, Ferrucci L, Fratino L, et
al: Validation of a multidimensional evaluation
scale for use in elderly cancer patients.
Cancer 77:395-401, 1996.
39. Repetto L, Venturino A, Fratino L, et
al: Geriatric oncology: A clinical approach to
the older patient with cancer. Eur J Cancer
40. Baker SD, Grochow LB: Pharmacology
of cancer chemotherapy in the older person.
Clin Geriatr Med 13:169-183, 1997.
41. Ershler WB, Longo DL: Aging and cancer:
Issues of basic and clinical science. J Natl
Cancer Inst 89:1489-1497, 1997.
42. Campisi J: Aging and cancer: The double-
edged sword of proliferative senescence. J
Am Geriatr Soc 45:482-488, 1997.
43. Balducci L, Extermann M: Cancer chemotherapy
in the older patient. Cancer
44. Borkowski JM, Duerr M, Donehower
RC, et al: Relation between age and clearance
rate of nine investigational anticancer drugs
from phase I pharmacokinetic data. Cancer
Chemother Pharmacol 33:493-496, 1994.
45. Begg CB, Elson PJ, Carbone PP: A
study of excess hematology toxicity in elderly
patients treated on cancer chemotherapy protocols,
in Yancik K, Yates JW (eds): Cancer
in the Elderly. An Approach to Early Detection
and Treatment, pp 149-163. New York,
Springer Verlag, 1989.
46. Chiara S, Lionetto R, Vincenti M, et al:
Advanced ovarian cancer in the elderly: Results
of consecutive trials with cisplatin-based
chemotherapy. Crit Rev Oncol Hematol 37:27-
47. Thyss A, Saudes L, Otto J, et al: Renal
tolerance of cisplatin in patients more than 80
years old. J Clin Oncol 12:2121-2125, 1994.
48. Nicoletto MO, Artioli G, Donach M, et
al: Elderly ovarian cancer treatment: Mitoxantrone-
carboplatin. Gynecol Oncol 80(2):221-
49. Gronlund B, Hogdall C, Hansen HH, et
al: Performance status rather than age is the
key prognostic factor in second-line treatment
of elderly patients with epithelial ovarian carcinoma.
Cancer 94:1961-1967, 2002.
50. Gershenson DM, Follen Mitchell M,
Atkinson N, et al: Age contrasts in patients
with advanced epithelial ovarian cancer: The
M. D. Anderson Cancer Center experience.
Cancer 71:638-643, 1993.
51. Bicher A, Sarosy G, Kohn E, et al: Age
does not influence taxol dose intensity in recurrent
carcinoma of the ovary. Cancer 71:594-